A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.
A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.
This registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with Transfusion Dependent, IPSS low or intermediate-1-Risk Myelodysplastic Syndrome (MDS), associated to a single abnormality of the chromosome 5 [del(5q)].
The purpose of this study is to collect additional data about the safety of an oral drug (lenalidomide, Revlimid®) that may have been prescribed to relieve anemia and decrease the need of blood transfusions. However, also patients affected by the MDS del(5q) who receive other treatments different from lenalidomide can be included in this study, if they agree.
Inclusion Criteria:
Exclusion Criteria:
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
No City Provided, New Jersey 00000, United States
Chemnitz, 09113, Germany
DĂĽsseldorf, 40225, Germany
Lebach, 66822, Germany
Leipzig, 04103, Germany
Mannheim, 68167, Germany
MĂĽnchen, 81675, Germany
Herakleion - Crete, 71110, Greece
Regio Calabria, 89100, Italy
Las Palmas de Gran Canaria, Canary Islands 35010, Spain
Santander, Cantabria 39008, Spain
LLobregat, 08908, Spain
Mallorca, 07120, Spain
Salamenca, 37007, Spain
Essex, CM1 7ET, United Kingdom
Essex, SS16 5NL, United Kingdom